Phase 2 N=637 Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Glaucoma · Open Angle or Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 20.07; 19.89 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Dietary Treatment of Crohn's Disease
Crohn's Disease · Inflammatory Bowel Disease
Primary: Number of Participants With Flare Up of Crohn's Disease Through Month 12 — 6; 4; 0 participants
Phase 1 N=21 A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
Healthy Subjects
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast — 3070; 2940; 850 ng*h/mL
Phase 2 N=45 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg
Phase 2 N=341 Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Gouty Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 31; 52; 9; 15 Participants
Phase 3 N=171 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
N/A N=760 Observational Study of Anti-Reflux Surgery
GERD · Gastroesophageal Reflux · Gastro Esophageal Reflux
Primary: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) — 4.2; 4.9 score on a scale
N/A N=28 Overcoming Barriers and Obstacles to Adopting Diabetes Devices
Type 1 Diabetes
Primary: Hemoglobin A1c (HbA1c) — 7.27; 6.73 percentage of HbA1c
Phase 2 N=116 Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
HIV Infections
Primary: Change From Baseline in Log10 Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Week 48 of the Double-blind Period — 4.52; 4.50; 4.62; -1.78 Log10 copies/mL…
N/A N=14 Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries
Burns
Primary: BTM 'Take' Rate — 95.22 percentage of BTM take per subject
Phase 3 N=816 Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
Malaria
Primary: Cure Rate on Day 28 — 197; 603 Participants — p=>0.05
Phase 2 N=20 Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Phase 1 N=30 Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria
Primary: Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period — 10; 10; 9; 10 participants
N/A N=193 Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Diabetes · Metabolic Syndrome
Primary: Systolic BP Pressure — 145; 144 mm Hg
Phase 1 N=8 111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Neoplasms
Primary: Number of Patients With Adverse Events — 2; 2; 2; 2 Participants